Artelo biosciences accepted into the alderley park oncology development program for fabp5 inhibitor biomarker development

Detection of elevated fabp5 associated with additional tumor types suggests the target for art26.12 may be more broadly relevant in cancer therapy

ARTL Ratings Summary

ARTL Quant Ranking